SMAD2 and soft tissue sarcoma: To highlight the clinical relevance of our findings, we examined the expression of SDMAD2 in the Memorial Sloan Kettering Cancer Center and Broad Institute (SKCC/BI) soft tissue sarcoma dataset, which revealed significant downregulation of SMAD2 in 47% of sarcoma patients in these cohorts (Fig. 6f).